UroToday2d
mCRPC with Bone Metastasis
Bone metastases are at the center of advanced prostate cancer care, with over 90% of patients with metastatic prostate cancer expected to have bone involvement. 1 These metastatic ...
UroToday3d
Clarity to Present COBRA and CLARIFY Abstracts at Two World-Leading Conferences
Two abstracts on Clarity’s diagnostic COBRA and CLARIFY trials with 64Cu-SAR-bisPSMA have been accepted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium ...
UroToday4d
Trends and Disparities in Prostate Cancer Mortality in the United States (1999-2020).
Prostate cancer is a leading cause of cancer-related mortality among men in the United States. Over the past two decades, the observed decline in prostate cancer mortality can be attributed to ...
UroToday6d
Mobilize the Troops! Military Involvement in the History of Testicular Cancer.
This review examines the historical evolution of testicular cancer (TCa) treatment, emphasizing the transformative impact of World War II. Prior to the war, cases of more than 50 testicular tumors ...
UroToday4d
Multi-level Factors to Build Confidence and Support in Active Surveillance for Low-Risk Prostate Cancer: A Qualitative Study.
Active surveillance (AS) is the guideline-recommended treatment for low-risk prostate cancer and involves routine provider visits, lab tests, imaging, and prostate biopsies. Despite good uptake, ...
UroToday4d
Continued Focus on Bone Metastases to Improve Outcomes and Patient Care in Prostate Cancer
Bone metastases are at the center of advanced prostate cancer care, with over 90% of patients with metastatic prostate cancer expected to have bone involvement. 1 These metastatic sites can be a cause ...
UroToday4d
Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study.
The RAVE-Renal study was conducted to evaluate the real-world efficacy and safety of avelumab plus axitinib as a first-line therapy for patients with metastatic renal cell carcinoma (mRCC). RAVE-Renal ...
UroToday5d
Development of an Orally Bioavailable CDK12/13 Degrader and Induction of Synthetic Lethality with AKT Pathway Inhibition - Beyond the Abstract
Advanced prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC), remains one of the most challenging malignancies to treat. While androgen-deprivation therapies and next ...
UroToday4d
Comparing PSA Screening Patterns and Their Role as Predictor of Prostate Cancer Diagnosis: Analysis of a Contemporary North American Cohort.
PSA screening remains a pivotal tool for early prostate cancer (PCa) detection. International guidelines rely on evidence from three major randomized clinical trials: ERSPC, PLCO, and CAP. We aim to ...
UroToday4d
Predictive value of Bladder EpiCheck® in detecting residual tumor before second TUR for non-muscle-invasive bladder cancer.
As Bladder EpiCheck® (BE) is a promising urinary biomarker for diagnosis and follow up of non-muscle-invasive bladder cancer (NMIBC), there are no studies evaluated this tool for second transurethral ...
UroToday2d
The Value and Limitations of Biopsies for Small Renal Masses - Phillip Pierorazio
The Value and Limitations of Biopsies for Small Renal Masses - Phillip Pierorazio ...